Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A plasma miRNA-based classifier for small cell lung cancer diagnosis

ABSTRACT: A plasma miRNA-based classifier for small cell lung cancer diagnosis

PROVIDER: PRJNA1005199 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25628900.fastq.gz	Fastqsanger.gz
	SRR25628901.fastq.gz	Fastqsanger.gz
	SRR25628865.fastq.gz	Fastqsanger.gz
	SRR25628866.fastq.gz	Fastqsanger.gz
	SRR25628867.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 37

Similar Datasets

A plasma miRNA-based classifier for small cell lung cancer diagnosis [miRNA-Seq]

Project description:Objectives: Small cell lung cancer (SCLC) is characterized by poor prognosis and challenging diagnosis. Screening in high-risk smokers results in a reduction in lung cancer mortality, however, screening efforts are primarily focused on non-small cell lung cancer (NSCLC). SCLC diagnosis and surveillance remain significant challenges. The aberrant expression of circulating microRNAs (miRNAs/miRs) is reported in many tumors and can provide insights into the pathogenesis of tumor development and progression. Here, we conducted a comprehensive assessment of circulating miRNAs in SCLC with a goal of developing a miRNA-based biomarker classifier to assist in SCLC diagnoses. Materials and Methods: We profiled deregulated circulating cell-free miRNA in the plasma of SCLC patients. We tested selected miRs on a training cohort and created a classifier by integrating miRNA expression and patient clinical data. Finally, we applied the classifier on a validation dataset. Results: We determined that miR-375-3p can discriminate between SCLC and NSCLC patients, and between SCLC and Squamous Cell Carcinoma patients. Moreover, we found that a model comprising miR-375-3p, miR-320b, and miR-144-3p can be integrated with race and age to distinguish metastatic SCLC from a control group. Conclusion: This study proposes a miRNA-based biomarker classifier for SCLC that considers clinical demographics with specific cut offs to inform SCLC diagnosis.

2023-10-31 | GSE240757 | GEO

A plasma miRNA-based classifier for small cell lung cancer diagnosis [NanoString]

2023-10-31 | GSE240758 | GEO

A plasma miRNA-based classifier for small cell lung cancer diagnosis [NanoString]

Project description:A plasma miRNA-based classifier for small cell lung cancer diagnosis [NanoString]

| PRJNA1005201 | ENA

A plasma miRNA-based classifier for small cell lung cancer diagnosis [miRNA-Seq]

Project description:A plasma miRNA-based classifier for small cell lung cancer diagnosis [miRNA-Seq]

| PRJNA1005200 | ENA

A plasma miRNA-based classifier for small cell lung cancer diagnosis.

Project description:IntroductionSmall cell lung cancer (SCLC) is characterized by poor prognosis and challenging diagnosis. Screening in high-risk smokers results in a reduction in lung cancer mortality, however, screening efforts are primarily focused on non-small cell lung cancer (NSCLC). SCLC diagnosis and surveillance remain significant challenges. The aberrant expression of circulating microRNAs (miRNAs/miRs) is reported in many tumors and can provide insights into the pathogenesis of tumor development and progression. Here, we conducted a comprehensive assessment of circulating miRNAs in SCLC with a goal of developing a miRNA-based classifier to assist in SCLC diagnoses.MethodsWe profiled deregulated circulating cell-free miRNAs in the plasma of SCLC patients. We tested selected miRNAs on a training cohort and created a classifier by integrating miRNA expression and patients' clinical data. Finally, we applied the classifier on a validation dataset.ResultsWe determined that miR-375-3p can discriminate between SCLC and NSCLC patients, and between SCLC and Squamous Cell Carcinoma patients. Moreover, we found that a model comprising miR-375-3p, miR-320b, and miR-144-3p can be integrated with race and age to distinguish metastatic SCLC from a control group.DiscussionThis study proposes a miRNA-based biomarker classifier for SCLC that considers clinical demographics with specific cut offs to inform SCLC diagnosis.

| S-EPMC10585112 | biostudies-literature

A plasma miRNA-based classifier for small cell lung cancer diagnosis

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-10-31 | GSE240759 | GEO

Identification of a robust methylation classifier for cutaneous melanoma diagnosis

Project description:Identification of a robust methylation classifier for cutaneous melanoma diagnosis

| PRJNA494817 | ENA

Analysis of plasma small RNAs prior to breast cancer diagnosis

Project description:Analysis of plasma small RNAs prior to breast cancer diagnosis

| PRJNA1001369 | ENA

Diagnosis potential of subarachnoid haemorrhage using miRNA signatures isolated plasma-derived extracellular vesicles

Project description:Diagnosis potential of subarachnoid haemorrhage using miRNA signatures isolated plasma-derived extracellular vesicles

| PRJNA924332 | ENA

A Diagnostic Classifier for Gene Expression-Based Identification of Early Lyme Disease

Project description:Lyme disease is a tickborne illness that causes an estimated 476,000 infections annually in the United States. New diagnostic tests are urgently needed, as existing antibody-based assays lack sufficient sensitivity and specificity. Using transcriptome profiling by RNA-Seq, targeted RNA sequencing, and machine learning (ML)-based classification of 218 subjects, we identified a 31-gene Lyme disease classifier (LDC) to discriminate early Lyme patients from “non-Lyme” controls infected with influenza, bacteremia, or tuberculosis or uninfected asymptomatic controls. Among the 31 classifier genes, 23 (74.2%) had previously been described in association with clinical investigations of Lyme disease patients or in vitro cell culture and rodent studies of Borrelia burgdorferi infection. Evaluation of the LDC using an independent test set of samples from 63 subjects (16 Lyme seropositive patients, 14 Lyme seronegative patients, and 33 controls) yielded an overall sensitivity of 90.0%, specificity of 100%, and accuracy of 95.2%. The LDC was positive in 85.7% of seronegative patients and persisted for ≥3 weeks in available longitudinal samples from 9 of 12 (75%) patients. These results highlight the potential clinical utility of a gene expression classifier for diagnosis of early Lyme disease.

2022-05-01 | GSE196192 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data